| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Euphorbia factor L7a modulates protein kinase signaling and induces apoptosis. It has demonstrated cytotoxic, anti-inflammatory, and antiviral properties. Due to its potent effects on cellular pathways, it is under investigation for anticancer drug development.
|
|---|---|
| ln Vitro |
In vitro, Euphorbia factor L7a exhibits cytotoxic activity against cancer cell lines, anti-inflammatory effects, and antiviral properties. Its mechanism involves modulation of protein kinase signaling and induction of apoptosis. The compound is a diterpenoid isolated from Euphorbia lathyris seeds.
|
| ln Vivo |
In vivo, Euphorbia factor L7a has potential anticancer, anti-inflammatory, and antiviral activities based on its in vitro effects. Animal studies are needed to confirm its in vivo efficacy and safety. Like many Euphorbia compounds, it may exhibit irritant or toxic effects requiring cautious handling.
|
| Enzyme Assay |
Cell-free assays for Euphorbia factor L7a: kinase inhibition is assessed using kinase activity assays with purified enzymes. Cytotoxicity is evaluated using cell-free systems such as enzyme inhibition assays (e.g., topoisomerase inhibition). Anti-inflammatory activity is assessed by measuring inhibition of COX-2 or LOX enzyme activities. The compound is incubated with enzymes or targets, and activity is measured spectrophotometrically. IC50 values are calculated.
|
| Cell Assay |
Cellular assays for Euphorbia factor L7a: cancer cell lines are cultured and treated with Euphorbia factor L7a at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is measured by MTT or CellTiter-Glo assays. Apoptosis is assessed by Annexin V/PI staining and caspase activity. Cell cycle analysis is performed by propidium iodide staining. Anti-inflammatory activity is evaluated by measuring cytokine production in LPS-stimulated cells.
|
| Animal Protocol |
In vivo animal studies for Euphorbia factor L7a: xenograft mouse models of cancer or animal models of inflammation would be used. Animals are administered Euphorbia factor L7a orally or intraperitoneally at doses of 10-50 mg/kg. Tumor growth, inflammatory markers, and toxicity are assessed. Due to potential irritant effects, careful monitoring is required.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Euphorbia factor L7a: as a lipophilic diterpenoid (MW 548.67), it may have moderate oral bioavailability. It is soluble in DMSO (25 mg/mL). The compound is a white to off-white solid. Storage: powder at -20°C for up to 3 years; in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Toxicity of Euphorbia factor L7a: like many Euphorbia compounds, it may exhibit irritant or toxic effects. Comprehensive toxicity data are limited. It is for research use only and not approved for clinical use. Standard laboratory safety precautions should be followed when handling.
|
| References | |
| Additional Infomation |
Euphorbia factor L7a is a research compound with potential applications in anticancer, anti-inflammatory, and antiviral research. It is a lathyrane-type diterpenoid from Euphorbia lathyris. Its mechanism involves protein kinase signaling modulation and apoptosis induction. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C33H40O7
|
|---|---|
| Molecular Weight |
548.67
|
| Exact Mass |
548.277
|
| CAS # |
93550-94-8
|
| PubChem CID |
154831605
|
| Appearance |
White to off-white solid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
634.8±55.0 °C at 760 mmHg
|
| Flash Point |
263.7±31.5 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.566
|
| LogP |
6.6
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
40
|
| Complexity |
1110
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC1=C[C@@H]2[C@H](CCC(=C[C@H]3[C@H]([C@@H](C)C[C@@]3(C1=O)OC(=O)C)OC(=O)/C=C/C4=CC=CC=C4)COC(=O)C)C2(C)C
|
| InChi Key |
NMTNFTPLDSEWKL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C33H40O7/c1-20-16-27-26(32(27,5)6)14-12-25(19-38-22(3)34)17-28-30(21(2)18-33(28,31(20)37)40-23(4)35)39-29(36)15-13-24-10-8-7-9-11-24/h7-11,13,15-17,21,26-28,30H,12,14,18-19H2,1-6H3
|
| Chemical Name |
[1-acetyloxy-10-(acetyloxymethyl)-3,6,6,14-tetramethyl-2-oxo-13-tricyclo[10.3.0.05,7]pentadeca-3,10-dienyl] 3-phenylprop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8226 mL | 9.1129 mL | 18.2259 mL | |
| 5 mM | 0.3645 mL | 1.8226 mL | 3.6452 mL | |
| 10 mM | 0.1823 mL | 0.9113 mL | 1.8226 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
